The major objective of this course is to provide a detailed insight into the practical aspects and approaches of process scale-up for different unit operations and technologies.
Topic insight by Amy Williams
The timelines for the implementation of IDMP have been extended (much to the relief of all stakeholders!).
This gives Industry an opportunity to ensure that we implement IDMP effectively within our companies; the successful identification of data sources, harmonization of data and alignment of relevant processes are all activities which should be started now. Due to the vast data requirements for IDMP, there is significant overlap with other projects within the EU Telematics Programme, and likely with internal company initiatives; the identification of these will be key to the success of internal company projects. Although the implementation of IDMP is a huge cross-functional challenge, it also provides us with a unique opportunity to leverage our expertise and knowledge, and align our initiatives for the successful and efficient completion of our projects.
Interested in this topic?
Targeted Drug Delivery
Gain detailed overview of the newest strategies in drug delivery and targeting.
Next Generation Antibody Therapeutics
This focused 2-day training will cover the discovery, engineering and production of next-generation antibodies, antibody fragments, bispecific Abs, innovative ADCs and more. Follow the path from their discovery and selection through engineering and expression to production and regulatory issues.
White Paper: Beyond the Cold Chain
Take a Good Look at the Future of Corporate Universities
There are four things corporate universities can do to avoid becoming irrelevant in the digital age.
Ready for the new GCP ICH E6 (R2) addendum?
On the 23rd of July 2015, the EMA's Committee for Human Medicinal Products released the Guideline for Good Clinical Practice E6(R2) for consultation. On the 14th of June 2017, it will come into effect and influence everyone involved in the clinical research process. What does it mean to pharma and biotech companies, sponsors, CROs, research institutes and third-party organizations?